Vycor Medical (VYCO) 10-Q 15 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 11, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'VYCOR MEDICAL INC	'
Entity Central Index Key	'0001424768	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	6,583,443

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets	'	'
Cash	$944	$59,821
Trade accounts receivable, net of allowance for doubtful accounts of $2,754 and $2,754	199,675	144,347
Other accounts receivable	75,000	'
Inventory	254,108	290,508
Prepaid expenses and other current assets	223,784	429,102
Total Current Assets	753,511	923,778
Fixed assets, net	728,320	827,389
Intangible and Other assets:	'	'
Trademarks	251,157	251,157
Patents, net of accumulated amortization	474,593	502,895
Website, net of accumulated amortization	1,848	2,772
Security deposits	53,169	53,169
Total Intangible and Other assets	780,767	809,993
TOTAL ASSETS	2,262,598	2,561,160
Current Liabilities	'	'
Accounts payable	357,203	187,789
Accrued interest: Related Party	203,034	107,176
Accrued interest: Other	130,424	87,962
Accrued liabilities	1,546,927	1,198,463
Other current liabilities	67,956	241,918
Notes payable: Related Party	2,283,556	1,732,812
Notes payable: Other	496,668	462,690
TOTAL CURRENT AND TOTAL LIABILITIES	5,085,768	4,018,810
STOCKHOLDERS' DEFICIENCY	'	'
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 17.34 and 39.3 issued and outstanding as at September 30, 2013 and December 31, 2012 respectively	1	1
Common Stock, $0.0001 par value, 1,500,000,000 shares authorized, 6,665,088 and 6,020,555 shares issued and outstanding at September 30, 2013 and December 31, 2012 respectively	667	602
Additional Paid-in Capital	13,612,134	13,141,489
Treasury Stock (103,334 and 68,889 shares of Common Stock as at September 30, 2013 and December 31, 2012 respectively, at cost)	-1,033	-1,033
Accumulated Deficit	-16,405,321	-14,587,914
Accumulated Other Comprehensive Income	-29,618	-10,795
Total Stockholders' Deficiency	-2,823,170	-1,457,650
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$2,262,598	$2,561,160

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Balance Sheets [Abstract]	'	'
Allowance for doubtful accounts receivable	$2,754	$2,754
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	17.34	39.3
Preferred stock, shares outstanding	17.34	39.3
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized	1,500,000,000	1,500,000,000
Common Stock, shares issued	6,665,088	6,020,555
Common Stock, shares outstanding	6,665,088	6,020,555
Treasury Stock, shares	103,334	68,889

Consolidated_Statement_of_Oper

Consolidated Statement of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Statement of Operations [Abstract]	'	'	'	'
Revenue	$321,630	$220,121	$788,258	$918,108
Cost of Goods Sold	41,806	25,374	99,718	145,044
Gross Profit	279,824	194,747	688,540	773,064
Operating expenses:	'	'	'	'
Research and development	'	33,650	52,635	104,197
Depreciation and Amortization	90,561	84,771	266,106	248,937
General and administrative	673,464	838,705	2,063,232	2,733,085
Negative Goodwill on Acquisition of Subsidiary	'	'	'	-66,394
Costs related to Acquisition of Subsidiary	'	'	'	18,285
Total Operating expenses	764,025	957,126	2,381,973	3,038,110
Operating loss	-484,201	-762,379	-1,693,433	-2,265,046
Other income (expense)	'	'	'	'
Other income (expense)	25,865	5,771	14,431	-9,449
Interest expense: Related Party	-34,081	-22,767	-95,859	-62,150
Interest expense: Other	-14,492	-12,734	-42,546	-36,629
Total Other expense	-22,708	-29,730	-123,974	-108,228
Net Loss	($506,909)	($792,109)	($1,817,407)	($2,373,274)
Loss Per Share	'	'	'	'
Basic and diluted	($0.08)	($0.14)	($0.29)	($0.42)
Weighted Average Number of Shares Outstanding	6,481,138	5,662,214	6,231,218	5,625,777

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net loss	($1,817,407)	($2,373,274)
Adjustments to reconcile net loss to cash used in operating activities:	'	'
Amortization of intangible assets	97,553	79,464
Depreciation of fixed assets	188,602	185,998
Share based compensation and expense	316,003	235,963
Changes in assets and liabilities:	'	'
Accounts receivable	-129,920	172,799
Inventory	36,457	-137,988
Prepaid expenses	27,718	218,497
Accounts payable	169,283	130,910
Accrued interest: Related Party	95,859	62,150
Accrued interest: Other	42,461	36,839
Accrued liabilities	346,094	331,958
Other current liabilities	-12,281	808
Cash used in operating activities	-639,578	-1,055,876
Cash flows used in investing activities:	'	'
Purchase of fixed assets	-88,813	-20,215
Acquisition of subsidiary, net of cash acquired	-163,201	-153,641
Acquisition of patents	-68,747	-56,291
Cash used in investing activities	-320,761	-230,147
Cash flows from financing activities:	'	'
Proceeds from issuance of Common Stock, net	332,832	170,000
Purchase of shares into Treasury Stock	'	-1,033
Net proceeds from issuance of Notes Payable: Related Party	550,744	293,050
Net proceeds from issuance of Notes Payable: Other	87,044	174,144
Repayment of Notes Payable: Other	-53,035	-34,666
Cash provided by financing activities	917,585	601,495
Effect of exchange rate changes on cash	-16,123	-2,657
Net decrease in cash	-58,877	-687,185
Cash at beginning of period	59,821	950,841
Cash at end of period	944	263,656
Supplemental Disclosures of Cash Flow information:	'	'
Interest paid:	88	197
Taxes paid	'	'
Non-Cash Transactions:	'	'
Common stock issued on conversion of Preferred C shares	1,100,000	900,000
Acquisition of subsidiary, net of cash acquired	'	'
Trademarks and Tradenames	'	121,157
Patents	'	180,183
Internally Developed Software	'	363,472
Other Net Assets	'	-758
Negative Goodwill on Acquisition	'	-66,394
Total assets acquired	'	597,660
Warrants, options and common stock issued for acquisition of subsidiary	'	-287,000
Deferred consideration payable	161,530	-161,640
Foreign exchange difference on deferred consideration	1,671	4,621
Acquisition of subsidiary, net of cash acquired, Net	$163,201	$153,641

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Basis of Presentation and Formation and Business of the Company [Abstract]	'
BASIS OF PRESENTATION	'
	1. BASIS OF PRESENTATION
	The consolidated financial statements of the Company present the financial position, results of operations, and cash flows of Vycor Medical, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive financial statements have been condensed or omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2012 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.
	The condensed consolidated financial statements for the three and nine months ended September 30, 2013 and 2012, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three months and nine months ended September 30, 2013 and 2012 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts have been reclassified to conform to the current presentation.

Formation_and_Business_of_the_

Formation and Business of the Company	9 Months Ended
	Sep. 30, 2013
Basis of Presentation and Formation and Business of the Company [Abstract]	'
FORMATION AND BUSINESS OF THE COMPANY	'
	2. FORMATION AND BUSINESS OF THE COMPANY
	Business Description
	Vycor Medical, LLC was formed on June 17, 2005 as a New York Limited Liability Company. The Company changed its name to Vycor Medical, Inc. and converted to a Delaware Corporation on August 14, 2007 and issued 107 shares of common stock in exchange for each of the 1,122 partnership units outstanding at date of conversion. The assets, liabilities and operations of the Company did not change pursuant to this reorganization, and the accompanying financial statements are presented as if the change occurred on the first day of the earliest period presented. Accordingly, all references to number of shares prior to the date of conversion are based upon the common stock equivalent of the partnership units outstanding on such dates.
	The Company designs, develops and markets neurological medical devices and therapies through two operating divisions: Vycor Medical and NovaVision. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals; NovaVision focuses on neuro-stimulation therapies and diagnostic devices for the treatment and screening of vision field loss.

Going_Concern

Going Concern	9 Months Ended
	Sep. 30, 2013
Going Concern [Abstract]	'
GOING CONCERN	'
	3. GOING CONCERN
	The Company’s financial statements have been presented on a basis that contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and assumes the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $1,817,407 for the nine months ended September 30, 2013, and the Company expects to incur additional losses. The Company has generated negative cash flows from operations since inception. As of September 30, 2013, current liabilities exceeded current assets by $4,332,257 the Company had a stockholders’ deficit of $2,823,170 and cash and cash equivalents of $944. The Company believes it will not have enough cash to meet its various cash needs unless the Company is able to obtain additional cash from the issuance of debt or equity securities. The Company intends to raise funds from the issuance of equity and/or debt securities, but there is no assurance that additional funds from the issuance of equity will be available for the Company to finance its operations on acceptable terms, or at all. If adequate funds are not available, the Company may have to delay development or commercialization of products or technologies that the Company would otherwise seek to commercialize, or cease operations. These conditions, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Significant_Accounting_Policie

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Significant Accounting Policies [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	4. SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation
	The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.
	Recent Accounting Pronouncements
	From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
	Software Development Costs
	The authoritative accounting guidance requires software development costs to be capitalized upon completion of the preliminary project stage. Accordingly, direct internal and external costs associated with the development of the features and functionality of the Company’s software, incurred during the application development stage, are capitalized and amortized using the straight-line method of the estimated life of five years once the software has been brought into service. During the three months ended September 30, 2013 the Company’s NeuroEyeCoach program completed the preliminary project stage, following which there was a capitalization of $61,167 of software development costs.
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:
		September 30,		September 30,
		2013		2012
	Stock options outstanding		5,557		5,557
	Warrants to purchase common stock		1,413,491		1,749,874
	Debentures convertible into common stock		368,726		368,726
	Preferred shares convertible into common stock		239,265		663,719
	Total		2,027,039		2,787,876

Notes_Payable

Notes Payable	9 Months Ended
	Sep. 30, 2013
Notes Payable [Abstract]	'
NOTES PAYABLE	'
	5. NOTES PAYABLE
	Related Party Notes Payable
	As of September 30, 2013 and December 31, 2012 Related Party Notes Payable consists of:
		30-Sep-13	31-Dec-12
	On December 29, 2009 and February 3, 2010, the Company issued convertible debentures in the amount of $371,362 and $70,000, respectively, payable to Fountainhead Capital Management (“Fountainhead”), the beneficial owner of more than 50% of the Company’s common stock. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $1.88 per share, subject to adjustment and does not require bifurcation. These debentures were originally due August 31, 2010 and the due date has been extended over time to December 31, 2013.	441,362	441,362
	On September 30, 2010 and October 14, 2010, the Company issued convertible debentures payable to Fountainhead in the amount of $85,000 and $90,000, respectively. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the	175,000	175,000
	Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $2.63 per share, subject to adjustment and does not require bifurcation. The debentures were originally due August 31, 2011, and the due date has been extended over time to December 31, 2013.
	On October 26, 2010 and November 15, 2010, the Company issued debentures payable to Fountainhead in the amount of $77,500 and $322,500, respectively. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The debentures were originally due August 31, 2011, and the due date has been extended over time to December 31, 2013.	400,000	400,000
	On November 15, 2010, the Company issued a convertible debenture in the amount of $350,000 payable to Peter Zachariou, a Director of the Company. This debenture accrues interest rate of 6% per annum, is secured by a first priority security interest in all of the assets of the Company, and is senior to or pari passuwith, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $2.85 per share, subject to adjustment and does not require bifurcation. On December 20, 2010, the Company repaid $50,000 of this debenture and removed the convertible rights. The debentures were originally due December 31, 2012 and the due date has been extended over time to December 31, 2013.	300,000	300,000
	In the period July to December 2012 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $300,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	300,900	300,900
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $115,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	115,550	115,550
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $325,744. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	325,744	-
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $210,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	210,000	-
	In the period July to September 2013 the Company issued short term, unsecured notes payable to David Cantor, in the aggregate amount of $15,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	15,000	-
	Total Related Party Notes Payable:	$2,283,556	$1,732,812
	Other Notes Payable
	As of September 30, 2013 and December 31, 2012 Other Notes Payable consists of:
		30-Sep-13	31-Dec-12
	On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company at the conversion price of $4.50 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended over time to November 30, 2013.	300,000	300,000
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $98,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	98,550	98,550
	In September 2012 the Company issued short term, unsecured notes payable to Osbaldo Trading Limited in the amount of $42,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	42,900	42,900
	In the period June to September 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $13,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	13,000	-
	Insurance policy finance agreements. During the nine months ended September 30, 2013 the Company received proceeds from Insurance policy finance agreement of $74,043 and made repayments of $53,035	42,218	21,240
	Total Other Notes Payable:	$496,668	$462,690
	As of September 30, 2013, $1,316,362 of Company's Related Party Notes Payable is secured by a security interest in all of the assets of the Company.
	The company assesses the value of the beneficial conversion feature of its convertible debt by determining the intrinsic value of such conversion, under ASC 470, at the time of issuance. At the time of issuance of each of the convertible debt instruments set out above, the fair value of the stock was either the same or less than the conversion price, and so there was no value attributable to any beneficial conversion feature.

Segment_Reporting_Geographical

Segment Reporting, Geographical Information	9 Months Ended
	Sep. 30, 2013
Segment Reporting, Geographical Information [Abstract]	'
SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	'
	6. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION
	(a) Business segments
	The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment.
		Three Months Ended September 30,		Nine Months Ended September 30,
		2013	2012	2013	2012
	Revenue:
	Vycor Medical	$225,823	$118,385	$502,847	$578,405
	NovaVision	95,807	101,736	285,411	339,703
	Total Revenue	$321,630	$220,121	$788,258	$918,108
	Gross Profit:
	Vycor Medical	$197,873	$109,058	$449,304	$487,853
	NovaVision	81,951	85,689	239,236	285,211
	Total Gross Profit	$279,824	$194,747	$688,540	$773,064
		September 30,	December 31,
		2013	2012
	Total Assets:
	Vycor Medical	$906,981	$1,055,026
	NovaVision	1,355,617	1,506,134
	Total Assets	$2,262,598	$2,561,160
	(b) Geographic information
	The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.
			Three Months Ended September 30,					Nine Months Ended September 30,
			2013			2012		2013		2012
	Revenue:
	United States		$	257,123		$	156,785	$	617,430	$	724,635
	Europe			64,507			63,336		170,828		193,473
	Total Revenue		$	321,630		$	220,121	$	788,258	$	918,108
	Gross Profit:
	United States		$	221,541		$	141,075	$	538,869	$	604,839
	Europe		$	58,283			53,672	$	149,671		168,225
	Total Gross Profit		$	279,824		$	194,747	$	688,540	$	773,064
			September 30,			December 31,
			2013			2012
	Total Assets:
	United States		$	1,713,278		$	1,935,638
	Europe			549,320			625,522
	Total Assets		$	2,262,598		$	2,561,160

Equity

Equity	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
EQUITY	'
	7. EQUITY
	Certain Equity Transactions
	During January to September 2013 the Company issued: 6,269 shares of Common Stock (valued at $15,000) to Steven Girgenti, 7,206 shares of Common Stock (valued at $15,000) to Dr. Oscar Bronsther and 2,892 shares of Common Stock (valued at $6,250) to Lowell Rush in consideration for services provided to the Board of Directors; and 2,253 shares of Common Stock (valued at $6,250) to Alvaro Pascual-Leone, 3,580 shares of Common Stock (valued at $9,375) to Josef Zihl and 3,075 shares of Common Stock (valued at $6,250) to Jason Barton and Jose Romano in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.
	On January 11, 2013, the Company filed a Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split of 1 for 150 on the issued and outstanding Common Stock par value $0.0001 (“Common Stock”). On January 15, 2013 (the “Effective Date”), the Company effectuated its reverse stock split. On the Effective date, the Company implemented a one for 150 share reverse split of its Common Stock. On the Effective Date, the Company’s pre-split 892,749,897 shares of Common Stock became 5,951,744 post-split shares of Common Stock, including the issuance of 66 shares of Common Stock for the round-up of partial shares. In connection with the reverse split, the Company’s authorized capital was not changed. All relevant information relating to the number of shares and per share information has been retrospectively adjusted to reflect the reverse stock split for all periods presented.
	In March 2013 GreenBridge Capital Partners, IV, LLC returned to Vycor all of the 34,445 shares being sought by the Company under an action filed by the Company in July 2012. These shares have been taken into Treasury Stock.
	During April and May 2013, the Company issued 47,590 and 32,152 shares of Common Stock respectively on exercise of warrants by Kenneth Coviello and Heather Vinas. The warrants had an exercise price of $1.08 and were exercisable on a cashless basis.
	During April to September 2013, Fountainhead Capital Management sold 177,439 warrants to purchase Vycor Common Stock at an exercise price of $1.88 per share. These warrants were granted to Fountainhead by the Company in February 2010 and were sold by Fountainhead to 7 investors at a price of $0.10 per warrant. The warrants were immediately exercised by the investors and the Company issued 177,439 shares of Common Stock in respect of the exercise and received cash proceeds of $332,832.
	During April to September 2013, the Company issued a total of 325,936 shares of Common Stock in respect of conversion of Series C Preferred Stock.
	On July 2, 2013, the Company entered into an advisory agreement with a registered broker-dealer to provide certain financial advisory services to the Company. Under the terms of the advisory agreement, the Company issued 15,000 restricted shares of Company Common Stock to the broker-dealer on execution.
	During July to September 2013, Del Mar and Alex Partners were issued 10,800 and 7,200 shares of Common Stock, respectively, valued at $21,600 and $14,400, respectively, in lieu of cash consulting fees for the months of July to September 2013.

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2013
Share-Based Compensation [Abstract]	'
SHARE-BASED COMPENSATION	'
	8. SHARE-BASED COMPENSATION
	Stock Option Plan
	The Company adopted the Vycor Medical, Inc Employee, Director, and Consultant Stock Plan (the “Plan”) as of February 13, 2008. The Plan provides for both incentive stock options and nonqualified stock options to be granted to employees, officers, consultants, independent contractors, directors and affiliates of the Company. The board of directors establishes the terms and conditions of all stock option grants, subject to the Plan and applicable provisions of the Internal Revenue Code. Incentive stock options must be granted at an exercise price not less than the fair market value of the common stock on the grant date. The options granted to participants owning more than 10% of the Company’s outstanding voting stock must be granted at an exercise price not less than 110% of the fair market value of the common stock on the grant date. The options expire on the date determined by the board of directors, but may not extend mare than 10 years from the grant date, while incentive stock options granted to participants owning more than 10% of the Company’s outstanding voting stock expire five years from the grant date. The vesting period for employees is generally over three years. The vesting Period for non-employees is determined based on the services being provided. The maximum number of shares of stock which may be delivered under the plan shall automatically increase by a number sufficient to cause the number of shares covered by the plan to equal 10% of the total number of shares of stock then outstanding on a fully diluted basis.
	Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option vesting period, the period during which an employee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable
	award on a straight-line basis. No employee stock options were granted for the nine month periods ended September 30, 2013 and 2012.
	Initial grants of options to purchase 500,000 shares were issued under the Plan on February 13, 2008 to each of Kenneth T. Coviello, the Company’s then Chief Executive Officer and then Heather N. Vinas, the Company’s President at an exercise price of $0.135 per share. The options vested 33-1/3% on each of the first, second, and third anniversary of the grant and expire February 12, 2018. Following Heather Vinas’ resignation as President of the Company in May 2010, 166,667 unvested options were cancelled. These options have been fully expensed.
	Stock appreciation rights may be granted either on a stand alone basis or in conjunction with all or part of any other stock options granted under the plan. As of June 30, 2013 there were no awards of any stock appreciation rights.
	The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date” using an option pricing model. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.
	The details of the outstanding rights, options and warrants and value of such rights, options and warrants are as follows:
	STOCK WARRANTS:	Number of shares			Weighted average exercise price
					per share
	Outstanding at December 31, 2011		1,747,341		$	3.07
	Granted		4,667			4.5
	Exercised		—			—
	Cancelled or expired		(2,140	)		36
	Outstanding at December 31, 2012		1,749,874		$	3.03
	Granted		—			—
	Exercised		(341,941	)	$	1.49
	Cancelled or expired		—			—
	Outstanding at September 30, 2013		1,407,933		$	3.4
	STOCK OPTIONS:	Number of shares			Weighted average exercise price
					per share
	Outstanding at December 31, 2011		5,557		$	20.25
	Granted		—			—
	Exercised		—			—
	Cancelled or expired		—			—
	Outstanding at December 31, 2012		5,557		$	20.25
	Granted		—			—
	Exercised		—			—
	Cancelled or expired		—			—
	Outstanding at September 30, 2013		5,557		$	20.25
	As of September 30, 2013, the weighted-average remaining contractual life of outstanding warrants and options is 1.16 and 4.38 years, respectively.
	Non-Employee Stock Compensation
	During the nine months ended September 30, 2013, the Company issued an aggregate of 6,269, 7,206 and 2,892 shares of common stock, respectively, valued at $15,000, $15,000 and $6,250 to each of Steven Girgenti, Oscar Bronsther and Lowell Rush for services rendered to the board of directors. For the nine months ended September 30, 2013, a total of $36,500 was recognized as share-based compensation for the issuance of these shares.
	During nine months ended September 30, 2013 the Company issued an aggregate of 2,253, 3,580 and 3,075 shares of common stock, respectively, valued at $6,250, to each of Alvaro Pascual-Leone, Jason Barton and Jose Romano and 2,261 shares of common stock valued at $9,375 to Josef Zihl for services rendered to the Scientific Advisory Board of NovaVision. For the nine months ended September 30, 2013, an aggregate of $28,125 was recognized as share-based compensation for the issuance of these shares.
	On November 30, 2012 the Company entered into 12 month consulting agreements with Del Mar Consulting, Inc and Alex Partners, LLC to provide investor relations and investor awareness consultancy services. Under these agreements, Del Mar and Alex Partners received shares Common Shares valued at $157,500 and $105,000 respectively. The value of these shares is being amortized over the period of the agreement, and for the nine months ended September 30, 2013 stock compensation of $196,875 was recognized as share-based compensation in connection with these agreements. During July to September 2013, Del Mar and Alex Partners were issued 10.800 and 7,200 shares of Common Stock, respectively, valued at $21,600 and $14,400, respectively, in lieu of cash consulting fees for the months of July to September 2013.
	On July 2, 2013, the Company entered into an advisory agreement with a registered broker-dealer to provide certain financial advisory services to the Company. Under the terms of the advisory agreement, the Company issued 15,000 restricted shares of Company Common Stock to the broker-dealer on execution, which were valued on the date of issuance at $37,500, which is being amortized over the first six months of the agreement. The value of these shares is being amortized over the six months of the agreement, and for the nine months ended September 30, 2013 stock compensation of $18,750 was recognized as share-based compensation in connection with this agreement.
	Aggregate stock-based compensation expense charged to operations for stock and warrants granted to the above non-employees for the nine months ended September 30, 2013 was $316,000. As of September 30, 2013, there was $175,000 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.
	Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing private placement purchase price. Expected volatility was based on the historical volatility of a peer group of publicly traded companies. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Constant Maturity rate.
	The following assumptions were used in calculations of the Black-Scholes option pricing model for options and warrants expensed in the nine months ended September 30, 2013 and 2012:
		Nine months ended September 30,
		2013			2012
	Risk-free interest rates		—			2.39%
	Expected life		—			3 years
	Expected dividends		—			0%
	Expected volatility		—			96%
	Vycor Common Stock fair value		—			$1.88-$3.38

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	9. COMMITMENTS AND CONTINGENCIES
	Lease
	The Company leases approximately 10,000 sq. ft located at 6401 Congress Ave., Suite 140, Boca Raton, FL 33487 from Catexor Limited Partnership for a gross rent of $14,260 plus sales tax per month. The term of the lease is 5 years and 6 months terminating July, 2017. The Company’s subsidiaries in Germany and the UK occupy properties on short term lease agreements. Rent expense for the nine months ended September 30, 2013 and 2012 were $49,569 and $48,084 respectively.
	Potential German tax liability
	In June 2012 the Company's German subsidiary received a preliminary assessment for Magdeburg City trade tax of approximately €75,000 (approximately $94,000). This assessment is for the 2010 fiscal year and relates to the Company's acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax for the same period has been preliminarily reduced to zero. The Company has not accepted this trade tax assessment and is in discussion with the relevant tax authorities with a view to its reduction. To the extent that this assessment, a higher or a reduced amount, is ultimately confirmed by the tax authorities, the Company believes it has a very strong claim against certain professional advisors which would offset the liability in full. Accordingly, the Company has made no provision for this liability for the nine months ending September 30, 2013 or the year ended December 31, 2012.
	Potential Patent Infringement
	The Company was made aware in 2012 that a competitor had been granted a patent, which infringed that already issued to Vycor. Following investigation, the Company has taken steps to initiate an invalidation of that patent and enforce its patent rights; the party is contesting our invalidation proceedings but the Company and its advisors believe it has a strong case. The Company has also been made aware that a second competitor has made a patent application which potentially infringes the Company is in the early stages of evaluation and has yet to determine what, if any actions to take in this instance, however as a general rule the Company intends to take all necessary action to protect its patent portfolio.. As with all patent infringement actions, there is some risk that the accused infringer will not be found to infringe the claims, and an additional risk that the accused infringer will successfully challenge the validity of the asserted claims.
	VBAS Limited Product Recall
	In August 2012 the Company initiated a limited product recall having identified a microscopic fiber in a single lot of its TC171105 model. Further investigation concluded that there was a very low incidence of this microscopic fiber in the lot, which had not been picked up during the manufacturer’s inspection process. The FDA was notified and all customers with units that had been distributed (a total of 5 customers in the U.S. and 2 customers internationally) were contacted and the units were recalled and replaced with re-inspected and passed units, or internationally re-inspected under 100% enhanced inspection guidelines; this recall and replacement process was completed in the US in September 2012 and internationally in November 2012 and there are no affected units on the marketplace. In January 2013, following their review, FDA classified the recall as a Class I and terminated the recall in May 2013.
	Vycor re-inspected all remaining units in the lot prior to shipment under 100% enhanced inspection procedures and took steps to ensure that this issue was contained to this lot and that other lots and products were not affected (this is one of 12 products sold by Vycor). The likely source of the fiber was identified and corrective steps implemented in both the manufacturing and inspection processes to ensure that the issue would not re-occur.
	Management believes that a decline in sales during February 2013 may have at least partially been the result of the posting by the FDA in late January 2013 of the Class 1 classification to the recall and which created some short-term market instability. Notwithstanding, for the period commencing March 1, 2013 and continuing through September 30, 2013, Vycor Medical’s sales have returned to pre-February 2013 levels and Vycor is not able at this time to determine whether there will be any additional financial impact on the Company as a result of this recall. Vycor’s customers have appreciated that Vycor took swift voluntary action to remove this product from the marketplace, even though the incidence of this fiber and therefore the risk was low, before any units could be used, and to maintain Vycor’s high safety and quality standards.

Consulting_and_Other_Agreement

Consulting and Other Agreements	9 Months Ended
	Sep. 30, 2013
Consulting and Other Agreements [Abstract]	'
CONSULTING AND OTHER AGREEMENTS	'
	10. CONSULTING AND OTHER AGREEMENTS
	The Company has entered into no new consulting or other agreements during the six months ended June 30, 2013. The following agreements remained in force during the period:
	Consulting Agreement with Fountainhead Capital Management Limited (“Fountainhead”)
	In October 2013, effective retroactively to May 5, 2013, the Fountainhead Consulting Agreement was extended on virtually the same terms as the Agreement expiring on that date. Pursuant to the Consulting Agreement, the Company pays Fountainhead a monthly retainer of $37,500. This monthly retainer shall be payable $5,000 in cash and the remainder shall be accrued and paid out to FCM at the option of FCM as follows: (i) in Vycor stock at any time at the average closing price for the 30 days prior to the end of the quarter in which the accrual is made; or (ii) in cash following the closing of a fundraising of no less than $2.5 million or on the sale of the Company or a substantial part of the assets thereof.
	Consulting Agreement with Del Mar Consulting Group, Inc and Alex Partners, LLC.
	On November 30, 2012 the Company entered into 12 month consulting agreements with Del Mar Consulting, Inc and Alex Partners, LLC to provide investor relations and investor awareness consultancy services. Under these agreements, Del Mar and Alex Partners received Common Shares valued at $157,500 and $105,000 respectively and cash of $7,200 and $4,800 respectively. Del Mar and Alex Partners agreed to take Vycor Common Stock in lieu of cash payments for July to September 2013.
	Advisory and Placement Agent Agreements
	On July 2, 2013, the Company entered into two agreements with a registered broker-dealer one to provide certain financial advisory services to the Company (“Advisory Agreement”) and the other to act as placement agent for the Company (“Placement Agent Agreement”).
	Under the terms of the Advisory Agreement, the broker-dealer is engaged on a non-exclusive basis to provide financial advisory services to the Company for at least ninety (90) days and thereafter until either party terminates the arrangement. Under the terms of the Advisory Agreement, the Company will issue 60,000 restricted shares of Company Common Stock to the broker-dealer, 15,000 of which are issuable on the date of the execution of the Agreement and 7,500 additional shares to be issued on a monthly basis commencing the 7th month following execution of the Agreement until the 12th month following execution of the Agreement. The Agreement also calls for the Company to reimburse certain out-of-pocket expenses.
	Under the terms of the Placement Agent Agreement, the Company engaged a broker-dealer as its exclusive placement agent until the later of (i) 90 days from the date of execution of the Agreement or (ii) the end of the offering period of any securities financing undertaken by the Company in connection with the Placement Agent Agreement. Normal placement agents fees and expense reimbursement will be payable. Any offering will be undertaken on a “best efforts” basis and the proceeds would be used for working capital and general corporate purposes.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	11. RELATED PARTY TRANSACTIONS
	During January to September 2013, the Company issued unsecured, subordinated loan notes to: Fountainhead for a total of $325,744; to Peter Zachariou, a director of the Company, for a total of $210,000; and to David Cantor, a director of the Company, for a total of $15,000. During October 2013, the Company issued unsecured, subordinated loan notes to Fountainhead for a total of $35,000. The loan notes are subordinated to the Company’s secured debentures and Preferred C Stock of the Company, bear interest at a rate of 6% are due on demand or by their one-year anniversary.
	In March 2013, Fountainhead and Peter Zachariou, a director of the Company, extended the maturity of secured loans totaling $1,016,362 and $300,000 respectively from March 31, 2013 to December 31, 2013.
	During April and May 2013, Fountainhead Capital Management sold warrants to purchase 177,439 shares of Vycor Common Stock at an exercise price of $1.88 per share. These warrants were granted to Fountainhead by the Company in February 2010 and were sold by Fountainhead to investors at a price of $0.10 per warrant share. The warrants were immediately exercised by the investors.
	There were no other related party transactions during the nine months ended September 30, 2013 other than the payment or accrual of fees under the Fountainhead Consulting agreement described in 10 above.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	12. SUBSEQUENT EVENTS
	The Company evaluated subsequent events through the date the financial statements were issued and filed with this Form 10Q.
	Share Issuance
	During October to November 2013, the Company issued 2,419 shares of Common Stock (valued at $5,000) to Steven Girgenti, in consideration for services provided to the Board of Directors; and 744 and 1,488 shares of Common Stock respectively (valued at $1,563 and $3,125 respectively) to Alvaro Pascual-Leone and Josef Zihl in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.
	Conversion of Preferred Shares
	During October to November 2013, the Company issued a total of 17,038 shares of Common Stock in respect of the conversion of Series C Preferred Stock.
	Loan Funding
	On October 23, 2013 the Company issued a term note for $100,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and is due November 30, 2013.
	During October, the Company issued unsecured, subordinated loan notes to Fountainhead for a total of $35,000. The loan notes are subordinated to the Company’s secured debentures and Preferred C Stock of the Company, bear interest at a rate of 6% are due on demand or by their one-year anniversary.
	Consulting Agreement with Fountainhead Capital Management Limited (“Fountainhead”)
	In October 2013, effective retroactively to May 5, 2013, the Fountainhead Consulting Agreement was extended on virtually the same terms as the Agreement expiring on that date. Pursuant to the Consulting Agreement, the Company pays Fountainhead a monthly retainer of $37,500. This monthly retainer shall be payable $5,000 in cash and the remainder shall be accrued and paid out to FCM at the option of FCM as follows: (i) in Vycor stock at any time at the average closing price for the 30 days prior to the end of the quarter in which the accrual is made; or (ii) in cash following the closing of a fundraising of no less than $2.5 million or on the sale of the Company or a substantial part of the assets thereof.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Significant Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
Software Development Costs	'
	Software Development Costs
	The authoritative accounting guidance requires software development costs to be capitalized upon completion of the preliminary project stage. Accordingly, direct internal and external costs associated with the development of the features and functionality of the Company’s software, incurred during the application development stage, are capitalized and amortized using the straight-line method of the estimated life of five years once the software has been brought into service. During the three months ended September 30, 2013 the Company’s NeuroEyeCoach program completed the preliminary project stage, following which there was a capitalization of $61,167 of software development costs.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:
		September 30,		September 30,
		2013		2012
	Stock options outstanding		5,557		5,557
	Warrants to purchase common stock		1,413,491		1,749,874
	Debentures convertible into common stock		368,726		368,726
	Preferred shares convertible into common stock		239,265		663,719
	Total		2,027,039		2,787,876

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Significant Accounting Policies [Abstract]	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'
		September 30,		September 30,
		2013		2012
	Stock options outstanding		5,557		5,557
	Warrants to purchase common stock		1,413,491		1,749,874
	Debentures convertible into common stock		368,726		368,726
	Preferred shares convertible into common stock		239,265		663,719
	Total		2,027,039		2,787,876

Notes_Payable_Tables

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2013
Notes Payable [Abstract]	'
Components of notes payable	'
		30-Sep-13	31-Dec-12
	On December 29, 2009 and February 3, 2010, the Company issued convertible debentures in the amount of $371,362 and $70,000, respectively, payable to Fountainhead Capital Management (“Fountainhead”), the beneficial owner of more than 50% of the Company’s common stock. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $1.88 per share, subject to adjustment and does not require bifurcation. These debentures were originally due August 31, 2010 and the due date has been extended over time to December 31, 2013.	441,362	441,362
	On September 30, 2010 and October 14, 2010, the Company issued convertible debentures payable to Fountainhead in the amount of $85,000 and $90,000, respectively. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the	175,000	175,000
	Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $2.63 per share, subject to adjustment and does not require bifurcation. The debentures were originally due August 31, 2011, and the due date has been extended over time to December 31, 2013.
	On October 26, 2010 and November 15, 2010, the Company issued debentures payable to Fountainhead in the amount of $77,500 and $322,500, respectively. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The debentures were originally due August 31, 2011, and the due date has been extended over time to December 31, 2013.	400,000	400,000
	On November 15, 2010, the Company issued a convertible debenture in the amount of $350,000 payable to Peter Zachariou, a Director of the Company. This debenture accrues interest rate of 6% per annum, is secured by a first priority security interest in all of the assets of the Company, and is senior to or pari passuwith, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $2.85 per share, subject to adjustment and does not require bifurcation. On December 20, 2010, the Company repaid $50,000 of this debenture and removed the convertible rights. The debentures were originally due December 31, 2012 and the due date has been extended over time to December 31, 2013.	300,000	300,000
	In the period July to December 2012 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $300,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	300,900	300,900
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $115,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	115,550	115,550
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $325,744. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	325,744	-
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $210,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	210,000	-
	In the period July to September 2013 the Company issued short term, unsecured notes payable to David Cantor, in the aggregate amount of $15,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	15,000	-
	Total Related Party Notes Payable:	$2,283,556	$1,732,812
	Other Notes Payable
	As of September 30, 2013 and December 31, 2012 Other Notes Payable consists of:
		30-Sep-13	31-Dec-12
	On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company at the conversion price of $4.50 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended over time to November 30, 2013.	300,000	300,000
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $98,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	98,550	98,550
	In September 2012 the Company issued short term, unsecured notes payable to Osbaldo Trading Limited in the amount of $42,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	42,900	42,900
	In the period June to September 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $13,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.	13,000	-
	Insurance policy finance agreements. During the nine months ended September 30, 2013 the Company received proceeds from Insurance policy finance agreement of $74,043 and made repayments of $53,035	42,218	21,240
	Total Other Notes Payable:	$496,668	$462,690

Segment_Reporting_Geographical1

Segment Reporting, Geographical Information (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting, Geographical Information [Abstract]	'
Business segments information	'
		Three Months Ended September 30,		Nine Months Ended September 30,
		2013	2012	2013	2012
	Revenue:
	Vycor Medical	$225,823	$118,385	$502,847	$578,405
	NovaVision	95,807	101,736	285,411	339,703
	Total Revenue	$321,630	$220,121	$788,258	$918,108
	Gross Profit:
	Vycor Medical	$197,873	$109,058	$449,304	$487,853
	NovaVision	81,951	85,689	239,236	285,211
	Total Gross Profit	$279,824	$194,747	$688,540	$773,064
		September 30,	December 31,
		2013	2012
	Total Assets:
	Vycor Medical	$906,981	$1,055,026
	NovaVision	1,355,617	1,506,134
	Total Assets	$2,262,598	$2,561,160
Summary of geographic information	'
			Three Months Ended September 30,					Nine Months Ended September 30,
			2013			2012		2013		2012
	Revenue:
	United States		$	257,123		$	156,785	$	617,430	$	724,635
	Europe			64,507			63,336		170,828		193,473
	Total Revenue		$	321,630		$	220,121	$	788,258	$	918,108
	Gross Profit:
	United States		$	221,541		$	141,075	$	538,869	$	604,839
	Europe		$	58,283			53,672	$	149,671		168,225
	Total Gross Profit		$	279,824		$	194,747	$	688,540	$	773,064
			September 30,			December 31,
			2013			2012
	Total Assets:
	United States		$	1,713,278		$	1,935,638
	Europe			549,320			625,522
	Total Assets		$	2,262,598		$	2,561,160

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Share-Based Compensation [Abstract]	'
Details of the outstanding rights, options and warrants and value of such rights, options and warrants	'
	STOCK WARRANTS:	Number of shares			Weighted average exercise price
					per share
	Outstanding at December 31, 2011		1,747,341		$	3.07
	Granted		4,667			4.5
	Exercised		—			—
	Cancelled or expired		(2,140	)		36
	Outstanding at December 31, 2012		1,749,874		$	3.03
	Granted		—			—
	Exercised		(341,941	)	$	1.49
	Cancelled or expired		—			—
	Outstanding at September 30, 2013		1,407,933		$	3.4
	STOCK OPTIONS:	Number of shares			Weighted average exercise price
					per share
	Outstanding at December 31, 2011		5,557		$	20.25
	Granted		—			—
	Exercised		—			—
	Cancelled or expired		—			—
	Outstanding at December 31, 2012		5,557		$	20.25
	Granted		—			—
	Exercised		—			—
	Cancelled or expired		—			—
	Outstanding at September 30, 2013		5,557		$	20.25
Assumptions used in calculations of the Black-Scholes option pricing model for options and warrants	'
		Nine months ended September 30,
		2013			2012
	Risk-free interest rates		—			2.39%
	Expected life		—			3 years
	Expected dividends		—			0%
	Expected volatility		—			96%
	Vycor Common Stock fair value		—			$1.88-$3.38

Formation_and_Business_of_the_1

Formation and Business of the Company (Details)	0 Months Ended	9 Months Ended
	Aug. 14, 2007	Sep. 30, 2013
	Unit	Operation
Formation and Business of the Company (Textual)	'	'
Common stock issued in exchange for partnership units	107	'
Number of partnership units outstanding	1,122	'
Number of operation divisions	'	2

Going_Concern_Details

Going Concern (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Going Concern (Textual)	'	'	'	'	'	'
Net loss	($506,909)	($792,109)	($1,817,407)	($2,373,274)	'	'
Stockholders' deficit	-2,823,170	'	-2,823,170	'	-1,457,650	'
Cash and cash equivalents	$944	$263,656	$944	$263,656	$59,821	$950,841

Significant_Accounting_Policie3

Significant Accounting Policies (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	2,027,039	2,787,876
Stock options outstanding [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	5,557	5,557
Warrants to purchase common stock [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	1,413,491	1,749,874
Debentures convertible into common stock [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	368,726	368,726
Preferred shares convertible into common stock [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	239,265	663,719

Notes_Payable_Details

Notes Payable (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Components of notes payable	'	'
Total Notes Payable:	$2,283,556	$1,732,812
Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	441,362	441,362
Convertible debentures issued on September 30, 2010 and October 14, 2010 [Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	175,000	175,000
Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	400,000	400,000
Convertible debenture issued on November 15, 2010 [Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	300,000	300,000
Short term, unsecured notes payable issued on July to December 2012 [Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	300,900	300,900
Short term, unsecured notes payable issued on August to December 2012 [Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	115,550	115,550
Short term, unsecured notes payable issued on January to September 2013 [Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	115,550	'
Short term, unsecured notes payable issued on January to September 2013 [Member] 1	'	'
Components of notes payable	'	'
Total Notes Payable:	210,000	'
Short term, unsecured notes payable issued on January to September 2013 [Member] 2	'	'
Components of notes payable	'	'
Total Notes Payable:	15,000	'
Term notes issued on March 25, 2011[Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	300,000	300,000
Short term issued in August to December 2012 [Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	98,550	98,550
Short term, unsecured notes payable issued September 2012 [Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	42,900	42,900
Unsecured loans issued in June to September 2013 [Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	42,218	'
Insurance policy finance agreements [Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	42,218	21,240
Other Notes Payable [Member]	'	'
Components of notes payable	'	'
Total Notes Payable:	$496,668	$462,690

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)

Sep. 30, 2013

Feb. 03, 2010

Dec. 29, 2009

Sep. 30, 2013

Sep. 30, 2010

Sep. 30, 2013

Oct. 14, 2010

Nov. 15, 2010

Oct. 26, 2010

Sep. 30, 2013

Nov. 15, 2010

Sep. 30, 2013

Dec. 20, 2010

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Mar. 25, 2011

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]

Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]

Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]

Convertible debentures issued on September 30, 2010 and October 14, 2010 [Member]

Convertible debentures issued on September 30, 2010 and October 14, 2010 [Member]

Convertible debentures issued on September 30, 2010 and October 14, 2010 [Member]

Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]

Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]

Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]

Convertible debenture issued on November 15, 2010 [Member]

Convertible debenture issued on November 15, 2010 [Member]

Convertible debenture issued on November 15, 2010 [Member]

Short term, unsecured notes payable issued on July to December 2012 [Member]

Short term, unsecured notes payable issued on July to December 2012 [Member]

Short term, unsecured notes payable issued on August to December 2012 [Member]

Short term, unsecured notes payable issued on August to December 2012 [Member]

Short term, unsecured notes payable issued on January to September 2013 [Member]

Short term, unsecured notes payable issued on January to September 2013 [Member]

Short term, unsecured notes payable issued on January to September 2013 [Member] 1

Short term, unsecured notes payable issued on January to September 2013 [Member] 2

Term notes issued on March 25, 2011[Member]

Term notes issued on March 25, 2011[Member]

Short term, unsecured notes payable issued September 2012 [Member]

Insurance policy finance agreements [Member]

Notes Payable (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of convertible debentures

'

$70,000

$371,362

'

$85,000

'

$90,000

$322,500

$77,500

'

$350,000

'

'

'

$300,900

'

$115,500

'

$98,550

$234,225

$13,000

'

'

'

$74,043

Term notes payables

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

Percentage of company's common stock hold by beneficial owner

'

50.00%

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate on debentures

'

6.00%

6.00%

'

6.00%

'

6.00%

6.00%

6.00%

'

6.00%

'

'

'

6.00%

'

6.00%

'

6.00%

6.00%

6.00%

'

'

'

'

Conversion price

'

$1.88

$1.88

'

$2.63

'

$2.63

'

'

'

$2.85

'

'

'

'

'

'

'

'

'

'

$0.03

'

'

'

Repayment of convertible debt

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate on term notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16.00%

'

'

'

Number of common stock purchased by issuance of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

Exercise price of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.50

'

'

'

Period of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

Debt instrument, maturity date, description

'

'

'

'

'

'

'

'

'

'

'

'

'

'Due on demand or one year after the issue date.

'

'Due on demand or one year after the issue date.

'

'Due on demand or one year after the issue date.

'

'Due on demand or one year after the issue date.

'Due on demand or one year after the issue date.

'

'

'Due on demand or one year after the issue date.

'

Debt instruments, original maturity date

'

31-Aug-10

31-Aug-10

'

31-Aug-11

'

'

31-Aug-11

31-Aug-11

'

31-Dec-12

'

'

'

'

'

'

'

'

'

'

25-Jun-11

'

'

'

Debt instruments, extended maturity date description

'

'

'

'Due date has been extended over time to December 31, 2013.

'

'Due date has been extended over time to December 31, 2013.

'

'

'

'Due date has been extended over time to December 31, 2013.

'

'Due date has been extended over time to December 31, 2013.

'

'

'

'

'

'

'

'

'

'

'Due date for this note has been extended over time to September 30, 2013.

'

'

Repayments of insurance policy

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53,035

Amount of notes payable secured by first security interest

$1,316,362

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Segment_Reporting_Geographical2

Segment Reporting, Geographical Information (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Revenue:	'	'	'	'	'
Total Revenue	$321,630	$220,121	$788,258	$918,108	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	279,824	194,747	688,540	773,064	'
Total Assets:	'	'	'	'	'
Total Assets	2,262,598	'	2,262,598	'	2,561,160
Vycor Medical [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Total Revenue	225,823	118,385	502,847	578,405	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	197,873	109,058	449,304	487,853	'
Total Assets:	'	'	'	'	'
Total Assets	906,981	'	906,981	'	1,055,026
NovaVision [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Total Revenue	95,807	101,736	285,411	339,703	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	81,951	85,689	239,236	285,211	'
Total Assets:	'	'	'	'	'
Total Assets	$1,355,617	'	$1,355,617	'	$1,506,134

Segment_Reporting_Geographical3

Segment Reporting, Geographical Information (Details 1) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Revenue:	'	'	'	'	'
Total Revenue	$321,630	$220,121	$788,258	$918,108	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	279,824	194,747	688,540	773,064	'
Total Assets:	'	'	'	'	'
Total Assets	2,262,598	'	2,262,598	'	2,561,160
United States [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Total Revenue	257,123	156,785	617,430	724,635	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	221,541	141,075	538,869	604,839	'
Total Assets:	'	'	'	'	'
Total Assets	1,713,278	'	1,713,278	'	1,935,638
Europe [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Total Revenue	64,507	63,336	170,828	193,473	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	58,283	53,672	149,671	168,225	'
Total Assets:	'	'	'	'	'
Total Assets	$549,320	'	$549,320	'	$625,522

Segment_Reporting_Geographical4

Segment Reporting, Geographical Information (Details Textual)	9 Months Ended
	Sep. 30, 2013
	Segment
Segment Reporting, Geographical Information (Textual)	'
Number of business segments	2
Number of geographic segments	2

Equity_Details

Equity (Details) (USD $)

0 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

2 Months Ended

9 Months Ended

3 Months Ended

Jan. 15, 2013

Mar. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Nov. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Nov. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

31-May-13

Sep. 30, 2013

31-May-13

31-May-13

31-May-13

Sep. 30, 2013

Sep. 30, 2013

Del Mar Consulting [Member]

Del Mar Consulting [Member]

Del Mar Consulting [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Alex Partners, LLC [Member]

Alex Partners, LLC [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Series C Preferred Stock [Member]

Steven Girgenti [Member]

Dr Oscar Bronsther [Member]

Alvaro Pascual - Leone [Member]

Josef Zihl [Member]

Fountainhead Capital Partners Limited [Member]

Jason Barton and Jose Romano [Member]

Kenneth Coviello [Member]

Heather Vinas [Member]

Investors [Member]

Lowell Rush [Member]

Investor

Equity (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation shares issued to nonemployees for services, share

'

'

'

'

'

'

10,800

'

'

'

7,200

6,269

7,206

2,892

2,253

'

3,580

'

'

'

3,075

'

Share-based compensation shares issued to nonemployees for services, value

'

'

'

'

$157,500

$21,600

$21,600

$196,875

$105,000

$14,400

$14,400

$15,000

$15,000

$6,250

$6,250

'

$9,375

'

'

'

$6,250

'

Effect of reverse stock split

'1 for 150

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, par value (in dollars per share)

$0.00

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common shares prior to reverse split

892,749,897

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction in number of shares as of stock split

5,951,744

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common shares issued for round up of partial shares

150

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares repurchased into Treasury Stock from GreenBridge Capital Partner

'

34,445

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued upon exercise of warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

47,590

32,152

177,439

'

'

Warrant exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.88

'

1.08

1.08

0.1

'

'

Warrants issued/sold to purchase shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

162,250

'

'

'

'

'

'

Number of investors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

'

'

Proceeds from exercise of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$332,832

'

'

Common stock issued upon conversion of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

325,936

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Stock Warrants [Member]	'	'
Details of the outstanding rights, options and warrants and value of such rights, options and warrants	'	'
Options Outstanding, Beginning Balance	1,749,874	1,747,341
Number of shares, Granted	'	4,667
Number of shares, Exercised	-341,941	'
Number of shares, Cancelled or expired	'	-2,140
Options Outstanding, Ending Balance	1,407,933	1,749,874
Weighted average exercise price per share, Outstanding, Beginning Balance	$3.03	$3.07
Weighted average exercise price per share, Granted	'	$4.50
Weighted average exercise price per share, Exercised	$1.49	'
Weighted average exercise price per share, Cancelled or expired	'	$36
Weighted average exercise price per share, Outstanding, Ending balance	$3.39	$3.03
Stock options [Member]	'	'
Details of the outstanding rights, options and warrants and value of such rights, options and warrants	'	'
Options Outstanding, Beginning Balance	5,557	5,557
Number of shares, Granted	'	'
Number of shares, Exercised	'	'
Number of shares, Cancelled or expired	'	'
Options Outstanding, Ending Balance	5,557	5,557
Weighted average exercise price per share, Outstanding, Beginning Balance	$20.25	$20.25
Weighted average exercise price per share, Granted	'	'
Weighted average exercise price per share, Exercised	'	'
Weighted average exercise price per share, Cancelled or expired	'	'
Weighted average exercise price per share, Outstanding, Ending balance	$20.25	$20.25

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Options and warrants expensed	'	'
Risk-free interest rates	'	2.39%
Expected life	'	'3 years
Expected dividends	'	0.00%
Expected volatility	'	96.00%
Vycor Common Stock fair value minimum	'	$1.88
Vycor Common Stock fair value maximum	'	$3.38

ShareBased_Compensation_Detail2

Share-Based Compensation (Details Textual) (USD $)

0 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

Jul. 02, 2013

Jul. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Nov. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Nov. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Feb. 29, 2008

Feb. 29, 2008

31-May-10

Feb. 29, 2008

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Stock options [Member]

Stock options [Member]

Stock Warrants [Member]

Stock Warrants [Member]

Del Mar Consulting [Member]

Del Mar Consulting [Member]

Del Mar Consulting [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Alex Partners, LLC [Member]

Alex Partners, LLC [Member]

Board of Directors Chairman [Member]

Scientific Advisory Board [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Consulting Agreement [Member]

Chief Executive Officer [Member]

President [Member]

President [Member]

Steven Girgenti [Member]

Dr Oscar Bronsther [Member]

Alvaro Pascual - Leone [Member]

Jason Barton [Member]

Jose Romano [Member]

Josef Zihl [Member]

Lowell Rush [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Share-Based Compensation (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ownership percentage of outstanding voting stock for the options to be granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'More than 10%.

'

'

'

'

'

'

'

'

'

'

'

Exercise price of options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Not less than 110% of the fair market value of the common stock on the grant date.

'

'

'

'

'

'

'

'

'

'

'

Option expired period determined by the board of directors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Not extend mare than 10 years from the grant date.

'

'

'

'

'

'

'

'

'

'

'

Outstanding voting stock expire from grant date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

Vesting period for employees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

Number of shares, Granted

'

'

'

'

'

'

4,667

'

'

'

'

'

'

'

'

'

'

500,000

'

500,000

'

'

'

'

'

'

'

'

Percentage of number of shares covered by plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

Exercise price per share

'

'

'

'

'

'

$4.50

'

'

'

'

'

'

'

'

'

'

$0.14

'

$0.14

'

'

'

'

'

'

'

'

Percentage of options vested on first anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

'

'

'

'

'

'

'

'

Percentage of options vested on second anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

'

'

'

'

'

'

'

'

Percentage of options vested on third anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

'

'

'

'

'

'

'

'

Grant expire date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12-Feb-18

'

'

'

'

'

'

'

'

'

'

'

Options cancelled or expired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

166,667

'

'

'

'

'

'

'

'

'

Share based compensation expenses

'

'

$316,000

'

'

'

'

'

'

'

'

'

'

'

$36,250

$28,125

'

'

'

'

'

'

'

'

'

'

'

$131,250

Weighted-average remaining contractual life of outstanding options

'

'

'

'4 years 4 months 17 days

'

'1 year 1 month 28 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation shares issued to nonemployees for services, share

'

'

'

'

'

'

'

'

'

10,800

'

'

'

7,200

'

'

'

'

'

'

6,269

7,206

2,892

3,075

2,319

2,261

1,078

'

Share-based compensation shares issued to nonemployees for services, value

'

'

'

'

'

'

'

157,500

21,600

21,600

196,875

105,000

14,400

14,400

'

'

'

'

'

'

15,000

15,000

6,250

6,250

4,688

9,375

2,500

'

consultancy agreement period

'

'

'

'

'

'

'

'12 months

'

'

'

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total unrecognized compensation costs related to warrant and stock awards and non-vested options

'

'

175,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period, Restricted Stock, shares

60,000

15,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued during period, Restricted Stock, value

'

$37,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_

Commitments and Contingencies (Details)	1 Months Ended		9 Months Ended
	Jun. 30, 2012	Jun. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
	USD ($)	EUR (€)	USD ($)	USD ($)
			sqft
Commitments and Contingencies (Textual)	'	'	'	'
Area of leased building (sq. ft)	'	'	10,000	'
Rent expenses plus sales tax (per month)	'	'	$14,260	'
Term of lease	'	'	'5 years 6 months	'
Lease expiration date	'	'	31-Jul-17	'
Approximate preliminary assessed trade tax	94,000	75,000	'	'
Description of Food and Drug Administration	'	'	'The FDA was notified and all customers with units that had been distributed (a total of 5 customers in the U.S. and 2 customers internationally) were contacted and the units were recalled and replaced with re-inspected and passed units, or internationally re-inspected under 100% enhanced inspection guidelines; this recall and replacement process was completed in the US in September 2012 and internationally in November 2012 and there are no affected units on the marketplace.	'
Rent expense	'	'	$49,569	$48,084

Consulting_and_Other_Agreement1

Consulting and Other Agreements (Details) (USD $)	0 Months Ended	1 Months Ended	5 Months Ended	1 Months Ended
	Jul. 02, 2013	Jul. 31, 2013	Sep. 30, 2013	Nov. 30, 2012	Nov. 30, 2012
			Fountainhead [Member]	Del Mar Consulting [Member]	Alex Partners, LLC [Member]
Consulting and Other Agreements (Textual)	'	'	'	'	'
Consulting agreement duration	'	'	'	'12 months	'12 months
Shares received under consulting agreement, value	'	'	'	$157,500	$105,000
Cash payment pursuant to consulting agreement	'	'	'	7,200	4,800
Payment of monthly retainer under consulting agreement	'	'	37,500	'	'
Maximum cash payment for consulting services (monthly)	'	'	$5,000	'	'
Stock issued during period, Restricted Stock, shares	60,000	15,000	'	'	'
Description of agreement	'	'(i) 90 days from the date of execution of the Agreement or (ii) the end of the offering period of any securities financing undertaken by the Company in connection with the Placement Agent Agreement.	'	'	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	9 Months Ended			2 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Nov. 30, 2013	31-May-13	Mar. 31, 2013	Sep. 30, 2013	Oct. 31, 2013	Mar. 31, 2013	Sep. 30, 2013	Sep. 30, 2013
				Subsequent Event [Member]	Fountainhead [Member]	Fountainhead [Member]	Fountainhead [Member]	Fountainhead [Member]	Peter Zachariou [Member]	Peter Zachariou [Member]	David Cantor [Member]
							Secured Loan One [Member]	Secured Loan One [Member]		Secured Loan One [Member]	Secured Loan One [Member]
								Subsequent Event [Member]
Related Party Transactions (Textual)	'	'	'	'	'	'	'	'	'	'	'
Loan amount	$2,283,556	'	$1,732,812	'	'	$1,016,362	$325,744	$35,000	$300,000	$210,000	$15,000
Interest rate on secured debentures and Preferred C Stock	6.00%	'	'	16.00%	'	'	'	'	'	'	'
Extended maturity date of secured loans	'From March 31, 2013 to December 31, 2013.	'	'	'	'	'	'	'	'	'	'
Restriction on sale of common stock	'	'The Agreement also requires Mrs Vinas not to sell more than 16,000 shares in any 30-day period.	'	'	'	'	'	'	'	'	'
Warrants sold to purchase shares	'	'	'	'	177,439	'	'	'	'	'	'
Warrant exercise price	'	'	'	'	$1.88	'	'	'	'	'	'
Warrant sale price	'	'	'	'	$0.10	'	'	'	'	'	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)

0 Months Ended

1 Months Ended

9 Months Ended

5 Months Ended

1 Months Ended

2 Months Ended

2 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

Jul. 02, 2013

Jul. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Nov. 30, 2012

Nov. 30, 2012

Oct. 31, 2013

Nov. 30, 2013

Oct. 23, 2013

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2013

Oct. 31, 2013

Aug. 09, 2013

Aug. 09, 2013

Aug. 31, 2013

Jul. 02, 2013

Jul. 31, 2013

Fountainhead [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Agreement

Steven Girgenti [Member]

Alvaro Pasual Leone [Member]

Josef Zihl [Member]

Fountainhead [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Craig Kirsch [Member]

Advisory Agreement [Member]

Issuance of Equity [Member]

Scientific Advisory Board [Member]

Subsequent Events (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares received under consulting agreement, value

'

'

'

'

'

$157,500

$105,000

'

'

'

$5,000

$1,563

$3,125

'

'

'

'

'

'

Shares received under consulting agreement, shares

'

'

'

'

'

'

'

'

'

'

2,419

744

1,488

'

7,200

4,800

'

'

15,000

Shares issued on conversion of Preferred stock, shares

'

'

'

'

'

'

'

'

17,038

'

'

'

'

'

'

'

'

'

'

Unsecured, subordinated loan notes issued

'

'

2,283,556

1,732,812

'

'

'

'

'

'

'

'

'

35,000

'

'

10,000

'

'

Interest rate on secured debentures and Preferred C Stock

'

'

6.00%

'

'

'

'

'

16.00%

'

'

'

'

'

'

'

'

'

'

Number of agreements

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

Restricted shares of common stock issuable under the agreement

60,000

15,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60,000

'

Restricted shares of common stock issuable on date of execution

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000

'

Additional shares issued on monthly basis from 7th month onwards

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,500

'

Term note issued to Euro American

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

Periodic Payment Made For Consulting Services

'

'

'

'

37,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum Cash Payment For Consulting Services

'

'

'

'

$5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description Of Accrued and Paid Of Consulting Fee At Option Of Consultant

'

'

'

'

'

'

'

'(i) in Vycor stock at any time at the average closing price for the 30 days prior to the end of the quarter in which the accrual is made; or (ii) in cash following the closing of a fundraising of no less than $2.5 million or on the sale of the Company or a substantial part of the assets thereof.

'

'

'

'

'

'

'

'

'

'

'